Protocol Ledger

NCT06828848 · Phase II · RECRUITING

A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections

Interventional Phase II clinical trial protocol NCT06828848 sponsored by Menarini Group in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-18 Enrollment: 44 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06828848
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)44 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06828848
Protocol FieldVerified Registry Value
NCT IdentifierNCT06828848
Consolidated Lead SponsorMenarini Group
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment44 participants (ESTIMATED)
Registered Start Date2025-02-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06828848
Hospital Research SiteLocationSite Profile
Azienda Ospedaliero Universitaria di ParmaParma, ItalyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI